Virtus Biotech Clinical Trials ETF
16 hedge funds and large institutions have $12.4M invested in Virtus Biotech Clinical Trials ETF in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
48% more capital invested
Capital invested by funds: $8.37M → $12.4M (+$4.05M)
45% more funds holding
Funds holding: 11 → 16 (+5)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
9.37% less ownership
Funds ownership: 39.02% → 29.65% (-9.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$374K |
| 2 |
Jane Street
New York
|
+$279K |
| 3 |
Morgan Stanley
New York
|
+$130K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$55.3K |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$937K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$332K |
| 3 |
LPL Financial
San Diego,
California
|
-$154K |
| 4 |
AWCI
Alpine Woods Capital Investors
Purchase,
New York
|
-$149K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6K |
BBC Hedge Fund Activity: Q4 2019 in Review
16 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2019, worth a combined $12.4M — up 48% from $8.37M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BBC positions and 2 closed out — a net gain of 5 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $374K. The largest seller was Royal Bank of Canada, cutting an estimated $937K.
- 16 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2019, up from 11 in Q3 2019.
- Funds reported $12.4M of Virtus Biotech Clinical Trials ETF stock for Q4 2019, up 48% quarter-over-quarter.
- 7 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2019 and 2 closed out, a net change of +5 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2019 was Susquehanna International Group, an estimated $374K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q4 2019 was Royal Bank of Canada, an estimated $937K sold.
Based on aggregated 13F filings for Q4 2019.